The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
Browsing: immunotherapy
iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour,…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered…
Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell…
Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone.…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…
LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed…
PRO in Pts With Rare Cancers: Pembrolizumab [2022] Â Patient reported Outcome (PRO) in patients with rare cancers (rare diseases)…
Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…